secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001628280-25-039878
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands
--------------------------------------------------------------------------------

- Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).
- Raised $64M ($50M public offering + $14M ATM) in July 2025; cash+investments $117.5M at June 30; runway into H1 2028.
- Expanded Almirall collaboration: second target elected for dermatology; up to $650M in potential milestones across two programs.
- ABS-101 Phase 1 interim data expected H2 2025; ABS-201 on track for Phase 1/2a start early 2026 with efficacy readout H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/0001628280-25-039878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/absc-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-039878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer